Blocking IL-1 beta reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation | ORKG Ask

We use cookies to provide a better user experience.

Data Protection

Related items

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

David A. Schaer
Richard P. Beckmann
Jack A. Dempsey
Lysiane Huber
Amelie Forest
Nelusha Amaladas
Yanxia Li
Ying Cindy Wang
Erik R. Rasmussen
Darin Chin
Andrew Capen
Carmine Carpenito
Kirk A. Staschke
Linda A. Chung
Lacey M. Litchfield
Farhana F. Merzoug
Xueqian Gong
Philip W. Iversen
Sean Buchanan
Alfonso de Dios
Ruslan D. Novosiadly
Michael Kalos

March 2018

Summary: Abemaciclib, an inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6), has recently been a...

An Interleukin-1 Signature in Breast Cancer Treated with Interleukin-1 Receptor Blockade: Implications for Treating Cytokine Release Syndrome of Checkpoint Inhibitors

Dinarello, C.A.

January 2018

Contains fulltext : 196421.pdf (publisher's version ) (Closed access)In this issue...

Why not treat human cancer with interleukin-1 blockade?

Dinarello, C.A.

January 2010

Contains fulltext : 87440.pdf (publisher's version ) (Closed access)The clinical s...

Improving cancer immunotherapy by targeting the STATe of MDSCs

Haas, N. de
Koning, C.
Spilgies, L.
Vries, I.J.M. de
Hato, S.V.

January 2016

Contains fulltext : 172778.pdf (Publisher’s version ) (Open Access)Cancer immunoth...

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

David A. Schaer
Richard P. Beckmann
Jack A. Dempsey
Lysiane Huber
Amelie Forest
Nelusha Amaladas
Yanxia Li
Ying Cindy Wang
Erik R. Rasmussen
Darin Chin
Andrew Capen
Carmine Carpenito
Kirk A. Staschke
Linda A. Chung
Lacey M. Litchfield
Farhana F. Merzoug
Xueqian Gong
Philip W. Iversen
Sean Buchanan
Alfonso de Dios
Ruslan D. Novosiadly
Michael Kalos

March 2018

Summary: Abemaciclib, an inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6), has recently been a...

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

David A. Schaer
Richard P. Beckmann
Jack A. Dempsey
Lysiane Huber
Amelie Forest
Nelusha Amaladas
Yanxia Li
Ying Cindy Wang
Erik R. Rasmussen
Darin Chin
Andrew Capen
Carmine Carpenito
Kirk A. Staschke
Linda A. Chung
Lacey M. Litchfield
Farhana F. Merzoug
Xueqian Gong
Philip W. Iversen
Sean Buchanan
Alfonso de Dios
Ruslan D. Novosiadly
Michael Kalos

March 2018

Summary: Abemaciclib, an inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6), has recently been a...